A5101669770- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Genetic factors in colorectal cancer
- Circular RNAs in diseases
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Metastasis and carcinoma case studies
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Mathematical Biology Tumor Growth
- Health and Medical Research Impacts
- HER2/EGFR in Cancer Research
Royal Marsden Hospital
2016-2025
Royal Marsden NHS Foundation Trust
2016-2025
Institute of Cancer Research
2007-2025
Imperial College London
2022-2024
Nanosyn (United States)
2016
Aberdeen Royal Infirmary
2009
National Health Service
2008-2009
Salisbury University
2009
St Luke's Hospital
2009
Plymouth Hospital
2009
We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil cisplatin, respectively, for untreated advanced esophagogastric cancer.
Cancer organoids to model therapy response are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches used predict drug responses clinic. They generated a live organoid biobank patients with metastatic gastrointestinal cancer who had previously been enrolled phase I or II clinical trials. This allowed authors compare how actually responded Encouragingly,...
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis resistance landscape in 35 RAS wild-type CRCs identified associations NF1 non-canonical RAS/RAF aberrations with primary validated CRC subtypes as non-genetic predictors benefit. Sixty-four percent biopsies acquired harbored no genetic drivers. Most these had switched from cetuximab-sensitive subtype at baseline to...
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Recruitment to clinical trials can be challenging and slower than anticipated. This prospective patient survey aimed investigate the proportion of patients approached about a trial who agree participate, their motivations for participation views on aspects cancer research.Patients had been in any Gastrointestinal Lymphoma Unit at Royal Marsden were invited complete questionnaire. The statistical analysis is mainly descriptive, with percentages being reported. Univariate logistic regression...
We report the final results of a prospectively randomized study that compared combination epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with standard 5-FU, doxorubicin methotrexate (FAMTX) in previously untreated patients advanced oesophagogastric cancer. Between 1992 1995, 274 adenocarcinoma or undifferentiated carcinoma were from eight oncology centres UK analysed for response survival. The overall rate was 46% (95% confidence interval (CI), 37–55%)...
To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) a multicenter, double-blind, prospective randomized study.Three hundred sixty-eight were randomly assigned to (300 mg twice daily) orally for 21 days every 28 or placebo 2:1 ratio. All received best supportive care. The primary end point was overall survival; secondary points progression free survival, tumor response, toxicity, and quality of life.The two treatment groups well balanced...
Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are undergoing chemotherapy limited.This was a prospective, exploratory analysis TEs randomized, controlled trial 964 recruited between 2000 2005 treated epirubicin/platinum/fluoropyrimidine combination for advanced/locally cancer. Regimens were epirubicin (E), cisplatin (C), fluorouracil (F; ECF); E, C, capecitabine (X; ECX); F, oxaliplatin (O; EOF);...
<h3>Background</h3> Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics investigate neoantigen presentation whether this augmented through interferon gamma (IFNγ) or MEK-inhibitor treatment. <h3>Methods</h3> Four microsatellite stable PDOs chemotherapy refractory one a treatment naïve CRC were expanded replicates with 100 million...
To compare cisplatin plus fluorouracil (FU) versus carboplatin paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen.
Pre-operative chemoradiotherapy (CRT) for MRI-defined, locally advanced rectal cancer is primarily intended to reduce local recurrence rates by downstaging tumours, enabling an improved likelihood of curative resection. However, in a subset patients complete tumour regression occurs implying that no viable present within the surgical specimen. This raises possibility surgery may have been avoided. It also recognised response CRT key determinant prognosis. Recent radiological advances enable...
Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1), demonstrated clinical activity across range solid tumors in trials. We present results from POD1UM-202 (NCT03597295), an open-label, single-arm, multicenter, phase II study evaluating retifanlimab patients with previously treated SCAC.Patients ≥18 years age...
Abstract Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use clinical practice. Experimental Design: Serial liquid biopsies were obtained at baseline monthly until disease progression mCRC treated a phase II trial (PROSPECT-R n = 40; NCT03010722) multicentric validation cohort (n 241). Tissue collected...
The purpose of the study was to establish optimal dose capecitabine (X) be used within a multicentre, randomised evaluating potential roles oxaliplatin (O) and X in chemonaive patients (pts) with advanced oesophagogastric cancer. Two by two design used, pts were one four regimens stratified for extent disease, performance status (PS) centre. treatment are epirubicin, cisplatin, 5-fluorouracil (ECF), EOF, ECX or EOX. Doses: E 50 mg m(-2), C 60 m(-2) O 130 i.v. 3 weekly; F 200 day(-1) 500...
The purpose of this study was to determine whether epirubicin, cisplatin and infused 5FU (ECF) improves overall survival (OS) compared 5FU, etoposide leucovorin (FELV) in patients with previously untreated advanced biliary cancer a prospective randomised study. Patients were randomly assigned receive ECF or bolus (FELV). primary end point OS secondary points objective response rate (ORR), failure-free (FFS), quality life (QOL) toxicity. In all, 54 recruited 27 each arm. median for 9.02...
Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. Design Patients RAS mutant mCRC biopsiable metastases were enrolled this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment at day 15 post-treatment. Median values volume transfer constant (K trans ), enhancing fraction (EF) their...